| Name | Title | Contact Details |
|---|---|---|
Jason Kawata |
Vice President of Technology, Food Division | Profile |
Samumed is a leader in medical research and development for tissue-level regeneration. With our platform`s origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.
SQZ Biotech is a unique cell therapy company, utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies. SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases.
Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.
Precision Diagnostics, a leader in clinical laboratory testing and medication adherence monitoring, is transforming healthcare through the delivery of comprehensive, insightful clinical data that can help improve patient outcomes and manage costs. Spec...